PPIB and Chagas disease: This targeting of the kinetoplastid mitochondrionis a key finding, suggesting Cytosporone B as a novel hit compoundand a starting point for the development of new antitrypanosomal agents.Moving forward, these results contribute to inform the next stageof hit-to-lead optimization, necessitating comprehensive structure-activityrelationship (SAR) studies around the Csn-B scaffold to refine itspotency, enhance its selectivity index, and optimize its pharmacokineticproperties, thereby positioning it as a promising prototype for futureexploration against Chagas disease.